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Abstract
Background: Several frameworks have been constructed to analyse the factors which influence and shape the
uptake of evidence into policy processes in resource poor settings, yet empirical analyses of health policy making
in these settings are relatively rare. National policy making for cotrimoxazole (trimethoprim-sulfamethoxazole)
preventive therapy in developing countries offers a pertinent case for the application of a policy analysis lens. The
provision of cotrimoxazole as a prophylaxis is an inexpensive and highly efficacious preventative intervention in HIV
infected individuals, reducing both morbidity and mortality among adults and children with HIV/AIDS, yet evidence
suggests that it has not been quickly or evenly scaled-up in resource poor settings.
Methods: Comparative analysis was conducted in Malawi, Uganda and Zambia, using the case study approach. We
applied the ‘RAPID’ framework developed by the Overseas Development Institute (ODI), and conducted a total of
47 in-depth interviews across the three countries to examine the influence of context (including the influence of
donor agencies), evidence (both local and international), and the links between researcher, policy makers and
those seeking to influence the policy process.
Results: Each area of analysis was found to have an influence on the creation of national policy on cotrimoxazole
preventive therapy (CPT) in all three countries. In relation to context, the following were found to be influential:
government structures and their focus, donor interest and involvement, healthcare infrastructure and other uses of
cotrimoxazole and related drugs in the country. In terms of the nature of the evidence, we found that how policy
makers perceived the strength of evidence behind international recommendations was crucial (if evidence was
considered weak then the recommendations were rejected). Further, local operational research results seem to
have been taken up more quickly, while randomised controlled trials (the gold standard of clinical research) was
not necessarily translated into policy so swiftly. Finally the links between different research and policy actors were
of critical importance, with overlaps between researcher and policy maker networks crucial to facilitate knowledge
transfer. Within these networks, in each country the policy development process relied on a powerful policy
entrepreneur who helped get cotrimoxazole preventive therapy onto the policy agenda.
Conclusions: This analysis underscores the importance of considering national level variables in the explanation of
the uptake of evidence into national policy settings, and recognising how local policy makers interpret
international evidence. Local priorities, the ways in which evidence was interpreted, and the nature of the links
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reproduction in any medium, provided the original work is properly cited.between policy makers and researchers could either drive or stall the policy process. Developing the
understanding of these processes enables the explanation of the use (or non-use) of evidence in policy making,
and potentially may help to shape future strategies to bridge the research-policy gaps and ultimately improve the
uptake of evidence in decision making.
Background
The creation of health policy is a political and social
process, in which local context can impact on the ways
in which evidence makes its way into national policy [1].
Yet rigorous policy analyses in resource poor settings
are rare, despite frameworks which have been con-
structed to help analyse and understand the various
influences that shape policy development in these con-
texts [2,3]. A recent overview of the health policy litera-
ture in low and middle income countries, concluded
with a call for analyses which consist of comparative,
multi-country studies; utilising rigorous case studies
which deliberately seek to explain health policy change
in these settings [4].
National policy making around cotrimoxazole (tri-
methoprim-sulfamethoxazole) preventive therapy (CPT)
in developing countries offers a particularly useful case
for the application of a policy analysis lens to issues in
health policy development. The provision of cotrimoxa-
zole as a prophylaxis is an inexpensive and highly effica-
cious preventative intervention in HIV infected
individuals. In Africa it works by reducing bacterial infec-
tion, malaria, and isosporiasis; reducing morbidity (by
43%) and hospital admission (by 23%) among children
with HIV/AIDS and reducing mortality (by 31%) and
morbidity (by 27%) among adults with HIV/AIDS [5,6].
Research demonstrating its efficacy in sub-Saharan Africa
was first published in 1999, and since then a number of
s t u d i e si na d u l t sa n do n ei nc h i l d r e nh a v eb e e np u b -
lished, providing a solid evidence base demonstrating its
efficacy, cost effectiveness and feasibility of implementa-
tion [5,7-20]. Yet, the policy response to CPT has varied
across Africa, with some countries not taking CPT into
policy at all, and others varying as to when it should be
prescribed (such as at different CD4 cell count levels
and/or different disease stages of patients [21]). Amongst
health researchers, frustration at the slow scale-up is evi-
dent: three separate papers in leading health journals
have sought to directly address the slow scale-up of CPT
in resource poor settings [21-23]. None, however,
addressed the issue of policy development in detail.
In order to understand the differential processes by
which CPT evidence has been taken up into national policy
in Africa, we present a report of comparative analysis (case
studies) of three African countries: Zambia, Malawi and
Uganda. These countries lend themselves to useful com-
parison for analysis. All are resource poor with generalised
HIV epidemics, limited health service infrastructure and
with high levels of bacterial resistance to cotrimoxazole. All
conducted research on the efficacy of CPT between 1999
and 2003 – although the research used different designs
(Zambia has provided the only randomised controlled trials
(RCT) on the efficacy of CPT in sub Saharan Africa since
2000). In policy terms, however, they responded very differ-
e n t l yt ot h eb o d yo fe v i d e n c eo nC P T .
This paper provides an analysis of the differing coun-
try policy processes, and provides a reflection and theo-
risation on ways in which context, evidence and
networks of researchers and policymakers influence pol-
icy development. The paper explains how the developing
country context influences the formation of local evi-
dence, the take up of international evidence, and the
shape and form of the networks of policy actors influen-
tial in these processes. It also explains the roles that
actors play to get research into policy and how these
roles depend on the types of barriers faced – barriers
which themselves arise from the national policy context
and the nature or understanding of the evidence itself.
Methods
To explore the factors influential in the research-to-pol-
icy process for CPT in the three low income countries,
we utilised the ‘RAPID’ (Research and Policy In Develop-
ment) framework developed by the Overseas Develop-
ment Institute (ODI) (see figure 1) [3,24] Constructed in
the recognition that policy making is a multi-dimensional
process, the RAPID framework has been applied to the
Figure 1 The ODI RAPID Framework
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oping countries [25-27]. This framework is particularly
useful for the purposes of our research, identifying
research evidence as just one of four elements which
shape policy development in developing countries [28].
Comparative analysis was conducted in Malawi,
Uganda and Zambia. Background research identified the
international evidence base for CPT, recommendations
made by key policy influencing bodies (the WHO,
UNAIDS, and UNICEF), and the policies on CPT in each
country. In-depth country case studies were conducted.
Published and unpublished documentation was supple-
mented with in-depth interviews with 47 stakeholders
involved either centrally or peripherally in the develop-
ment of the cotrimoxazole policy (15 in Malawi, 15 in
Uganda and 17 in Zambia). These stakeholders were
drawn from government, national and international non-
governmental organisations, multilateral agencies,
research institutions and hospitals. The sampling was
both purposive and used snowball techniques. We devel-
oped an interview guide in English which followed
themes of the RAPID framework. This guide was divided
into four subject areas process, context, evidence and
links. The first allowed for an overall description of the
research to policy process and the three subsequent areas
for discussion were used to gain data on the ways in
which the process was structured by these factors. All
Interviews were recorded and transcribed by the lead
researcher (EH). The analysis utilised the Nvivo qualita-
tive software analysis package, with highest level data
coding following the three main areas of analysis: con-
text, evidence and links. A three page document detailing
the main findings of the country case studies was pro-
duced for each country. All informants had the opportu-
nity to read this document and comment on the findings
from their own country study: modifications and clarifi-
cations to the research findings were made accordingly.
At the beginning of each interview, research aims were
described and informed consent was secured. All efforts
to render the participants anonymous in any papers
published have been made, but due to the nature of pol-
icy making (small numbers of often high profile partici-
pants), it was explained that it was not possible to
provide complete anonymity. Key informants had the
opportunity to state that they did not want to quoted,
even anonymously. The key informants are identified in
the text only by the country study which they belong to,
their anonymous informant number, and the date on
which they were interviewed.
Results
International research and recommendations
In the 1990s, two clinical trials on the efficacy of CPT
were undertaken in Cote d’Ivoire [7,8]. The results
showed that CPT was effective at an early stage of HIV
disease: reducing morbidity and mortality in HIV
infected TB patients, and reducing severe clinical events
in HIV infected adults [7,8]. Following the release of
these results, the WHO and UNAIDS released provi-
sional recommendations that CPT be given to all HIV
infected adults with a CD4 count of 500 cells/mm3 or
less, or with WHO clinical stage 2-4, to all infants HIV-
infected or HIV-exposed; and to all children over the
age of 15 months with symptomatic HIV disease [29].
These recommendations were somewhat controversial,
as many researchers in other country settings were not
sure of the generalisability of the research findings
across Africa.
The publication of the provisional recommendations,
however, resulted in the halting or redesign of three
other placebo-controlled trials underway on CPT in
Malawi, Senegal and South Africa [11,15,30]. At national
level in many African countries the provisional recom-
mendations were considered to be based on insufficient
evidence to justify their implementation. This was pri-
marily as the Cote d’Ivoire studies were conducted in an
area of low bacterial resistan c et oc o t r i m o x a z o l e ,w h i l e
much of southern Africa is known to have high bacterial
resistance to the drug [21]. Over the following eight
years, a further nine major studies were conducted into
the efficacy of CPT for HIV related illness, including spe-
cific studies for HIV infected patients with tuberculosis
(TB) [5,9,12,13,15-17,31,32]. All but one of these studies
were conducted in areas of high bacterial resistance to
cotrimoxazole (the remaining one, based in South Africa
[9], did not state levels of resistance) and all but one
study [31] reported significant impacts on either mortal-
ity, morbidity or both among HIV infected patients.
National policy responses
Additional file 1 shows the key research and policy
events at both international and national level for each
country. Of the three, Malawi was the first to begin
research on CPT, focusing on its use for HIV infected
TB patients. Funding for the first Malawian trial was
halted following the publication of research results in
Cote d’Ivoire. It was re-designed without its control arm
to examine the efficacy of two different doses of CPT
and compare these to historical data [11]. This was one
of five efficacy or feasibility studies which were either
complete or underway by 2002, when the Malawi gov-
ernment agreed to a phased scale-up of CPT for HIV
infected TB patients (both before and after treatment
for TB) [15,17,33-35].
In Uganda, interviewees reported that the government
initially rejected the request by the United States Cen-
ters for Disease Control and Prevention based in
Uganda (CDC/Uganda) and the local NGO The AIDS
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clinics, requesting instead data on the efficacy of CPT in
Uganda (an area of high bacterial resistance) (UKI 2 16/
12/2009; UKI 9 20/01/2010). Two observational studies
were subsequently conducted [13,16], and in 2003 the
Ministry of Health agreed that CPT could be scaled up
by CDC/Uganda, the UK Medical Research Council
Uganda Virus Research Institute (MRC UVRI) and
TASO. At the time, the government rejected the
national scale-up of CPT as they had outstanding ques-
tions about cost and the best way of reducing opportu-
nistic infections among HIV infected patients (such as
investment in safe water supply) (UKI 7 28/01/2010).
Following two years of lobbying and activity by CDC/
Uganda, during which time further evidence on the effi-
cacy of CPT in areas of high bacterial resistance
emerged, the government agreed in 2005 to a broad
national policy on the scale up of CPT for all HIV infect
adults and HIV infected and exposed children [5].
The same year (2005), primarily on the basis of the
research from Uganda and Zambia, the Malawian HIV
Programme adopted a broader policy, providing CPT
for HIV infected adults and children with and without
TB. In Zambia an RCT on the efficacy of CPT among
HIV infected children released research results in 2003
(the results of the RCT on the efficacy of CPT among
HIV positive TB patients were not published until 2008
and the results of the third RCT on the efficacy of CPT
among HIV positive post-partum women have not yet
been released [32]). The results of the paediatric study
showed that CPT was highly effective at reducing mor-
bidity and mortality despite high levels of bacterial resis-
tance to cotrimoxazole [5]. Although these findings,
published in 2004, came from within Zambia, scale-up
of CPT was not undertaken by the National AIDS
Council on the basis that there was no sufficient infra-
structure or funding to ensure its provision. It was not
until 2006 that the government agreed to a policy of
providing CPT for HIV related illness. The following
year detailed guidelines were published.
In addition to these different timelines to policy devel-
opment, the content of national CPT policies also had
some differences between our three case study coun-
tries. Additional file 2 summarises and compares the
content of the three countries’ CPT policies.
Explaining uptake and use of research in policy
Despite similarities in terms of level of economic devel-
opment, burden of HIV and common concerns with
bacterial resistance, the three countries illustrate differ-
ent pathways from evidence to policy on CPT, and dif-
ferences in policy content. We explored these research-
to-policy processes explicitly through the use of the
RAPID framework to identify the key factors at play,
and how they interact to shape the uptake of research
evidence in low-income countries.
Context
The first area to be explored was the health policy con-
text. This was taken to broadly include the institutional
structures in place through which policy is made in
each settings, as well as the political agendas and issues
facing policy makers in HIV. In our comparison, four
main areas were most important in shaping the develop-
ment of CPT policy:
￿ Government structures and their focus
￿ Donor interest and involvement
￿ Healthcare infrastructure
￿ Other uses of cotrimoxazole and related drugs in the
country
The focus of the existing government organizations
was critically important in all countries. In 2002, Mala-
wian national HIV programming was focused on pre-
vention. Lacking a bio-medical approach, it left staff
relatively disinterested in the potential that CPT had to
reduce HIV related infections (MKI 13 6/11/2009, MKI
6 16/2/2009, MKI 8 17/02/2009). In marked contrast,
the Malawian National Tuberculosis Control Pro-
gramme was actively seeking bio-medical interventions
that could reduce the high numbers of deaths among
HIV infected TB patients, which led to CPT being seen
as an attractive option by this body (MKI 13 12/11/
2009, MKI 9, 11/02/2009, MKI 6 16/02/2009, MKI 2
22/2/2009). According to one policy maker:
“The TB programme was seeing a lot of mortality in
TB and HIV patients and we did not have anything to
give these patients. So you find that the TB programme
was strong, it was mature and well organised, but we
had not much to offer directly to patients who were co-
infected and this was the starting point for the pro-
gramme.” (MKI 13 12/11/2009)
However, interest in pursuing a bio-medical approach
to HIV did not guarantee interest in CPT in all settings.
In Zambia, interviewees reported a biomedical focus,
but within this an emphasis on anti-retrovirals (ARVs)
at the exclusion of CPT over CPT (ZKI 3, 26/09/2008).
Interest in ARVs in Zambia was politically charged, with
the explicit involvement of the President of Zambia in
seeking nationwide access through the public sector.
“At the time that we started with the ARV programme
the donors strongly felt that Africa did not have the
capacity to handle ARVs, so the first ARVs that were
bought in Zambia were bought by the Zambian govern-
ment. The donors provided kits for testing for HIV but
they did not think that we should have an ARV pro-
gramme.” (ZKI 8 10/11/2009)
According to one informant, this heightened focus on
ARVs simply meant that policy makers were less
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the important research results of the efficacy of CPT
(ZKI 3, 26/09/08). According to another informant, the
emphasis on ARVs at the exclusion of CPT was consid-
ered to be because it was difficult to scale up both
ARVs and CPT at the same time (ZKI 8 10/11/2009).
Of all of the countries in our study, the development
of CPT policy in Uganda was apparently the most expli-
citly influenced by a donor organisation. In 1999 CDC/
Uganda had funds for programmatic work and were
looking for low cost interventions to prolong the lives of
those with HIV (UKI 9 29/01/2010). The CDC had been
involved in the research on CPT in Cote d’Ivoire, and
senior personnel in the Ugandan CDC office were keen
to fund the implementation of CPT within clinics being
run by the Ugandan NGO, TASO (UKI 2, 16/12/2009;
UKI 11, 8/02/2010). CDC/Uganda had access to funding
for CPT; expertise and funding to conduct a study of its
efficacy (when evidence was requested by the govern-
ment); and the means to support the policy develop-
ment process. It was perceived to be active throughout
the policy development process (UKI 2, 16/12/2009,
UKI 3 17/12/2009, UKI 9, 29/01/2010, UKI 10, 11/02/
2010, UKI 14, 15/03/2010). According to one researcher:
The Ugandan government were uncomfortable with the
international data so the CDC conducted the Ugandan
study on the use of cotrimoxazole. As soon as they com-
pleted this study, they approached the ministry of health
again…..As soon as the MOH gave [the CDC] the go
ahead, gave the technical teams the go ahead to develop
their policy, [the CDC] worked with the technical staff at
the Ministry of Health to draft the initial draft of the
policy guidelines.... The CDC has the advantage of being
able to support policy development but also has addi-
tional resources to help the implementation of policy. For
cotrimoxazole, the amount of money that was being put
aside for the cotrimoxazole, the CDC agreed with the
MOH that it would help and it committed substantial
resources in terms of the amount of cotrimoxazole
required. (KI 14, 15/ 03/2010)
In Malawi and Zambia, donor agencies were not seen
as having such a direct role in the creation of local
research or shaping of policy, despite being involved in
providing funds for the research in both countries,
either directly (through the UK’s Department for Inter-
national Development Zambian office for the Zambian
trials) or through national programming (a variety of
donor agencies through the TB Programme in Malawi).
In all countries, the structural and economic feasibility
(i.e. having a healthcare infrastructure and sufficient
funds) of implementing CPT was a further concern at
the point at which national policy was considered and
either developed or rejected. Within Uganda and
Malawi, the partial scale-up of CPT was expected to
(and did) occur within well-established health pro-
grammes (TASO and the National TB Control Pro-
gramme, respectively), in which clinics were already
providing care to HIV infected patients. CPT could be
added to an already functioning structure providing care
to HIV infected patients, and in both cases funds were
known to be available to purchase cotrimoxazole. In
Zambia, policy makers had been concerned about the
lack of infrastructure through which CPT could be pro-
vided to patients, and this was considered to be a major
obstacle to policy creation (ZKI 13, 23/10/2008, ZKI 15
28/10/09). One medical doctor involved in the discus-
sion of cotrimoxazole at national level argued:
[the concern was] whether it was feasible to [imple-
ment cotrimoxazole], it was the cost - can we afford to
do this - and how will we do it. At the time we had
ARVs in three pilot sites, so we could accompany the
ARVs with cotrimoxazole but we weren’te v e r y w h e r e …..
people were thinking that this is good, this is something
that we could do but how. So, it depended between the
“how” for all of these years. (ZKI 13 23/10/2008)
The fact that policy makers were willing to consider
the development of infrastructure to provide ARVs
means that lack of infrastructure is not an insurmounta-
ble problem (structures can be developed). The combi-
nation of lack of infrastructure with the relatively low
perceived priority of CPT (compared with ARVs), seems
to have created a context in Zambia in which CPT was
not able to be adopted into policy as early as in the
comparison countries. Only later, when ARVs had been
scaled up and with the necessary healthcare infrastruc-
ture in place, was it seen as feasible to adopt CPT in
Zambia.
The final point about the healthcare contexts relates
to concerns raised about the potential for CPT to
increase resistance to cotrimoxazole and related drugs.
These concerns were raised in both Malawi and Uganda
(but not Zambia). In those countries sulfadoxine/pyri-
methamine (SP) (which belongs to the same class of
antibiotics as cotrimoxazole) was used as (part of) the
first line for malaria treatment. Concerns were raised by
those involved in malaria programming and research in
both countries that the widespread use of CPT might
render SP ineffective (MKI 13, 12/11/2009, MKI 12, 18/
02/2009, MKI 10, 20/2/2009, MKI 6, 16/02/2009, MKI
5, 15/02/2009, MKI 4 29/01/2009, MKI 2, 27/02/2009).
Cotrimoxazole was also used to treat respiratory infec-
tions in both countries, although the use of cotrimoxa-
zole for this purpose was highlighted more by Ugandan
rather than Malawian informants (UKI 8, 29/01/2010,
UKI 2, 16/12/2009, UKI 3, 17/12/2009). However, by
the time the 2005 policy was created in both Malawi
and Uganda, both countries had changed their first line
treatment for uncomplicated malaria away from SP and
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relevant.
Evidence
In all three countries studied, the 2000 WHO/UNAIDS
provisional recommendations were considered to be
based on insufficient evidence to justify implementation.
This was primarily because Cote d’Ivoire is an area of
low bacterial resistance to cotrimoxazole. In Uganda,
the Government was also concerned that widespread
use of CPT would create further resistance to cotrimox-
azole (rendering it useless as a treatment), and in
Malawi the government considered the spectrum of dis-
eases in HIV infected patients to be different to those in
Cote d’Ivoire (UKI 9 29/01/2010; MKI 7 17/02/2009).
Following the publication of the 2000 WHO/UNAIDS
recommendations, in both Malawi and Uganda the gov-
ernment considered that further trials would no longer
be considered ethical. This left the countries in the diffi-
cult position of having insufficient evidence to warrant
implementation but unable to undertake experimental
trials. Criticism of the publication of the 2000 WHO/
UNAIDS recommendations was most outspoken in
Malawi, where UNAIDS funding for a randomised trial
measuring the efficacy of CPT in reducing mortality and
morbidity among HIV positive patients with active
tuberculosis was suspended [36]. Two Malawian infor-
mants argued that the publication of the 2000 recom-
mendations had been counter-effective, slowing the
provision of CPT across the region (MKI 2, 27/02/2009,
MKI 7 17/02/2009). One researcher argued:
If you look at the letter written to the Lancet, it said
that this was completely the wrong decision of UNAIDS
[to publish the 2000 guidelines], because there were stu-
d i e sg o i n go ni nM a l a w i ,C a p eT o w n ,a n dS e n e g a l .A l l
three of those studies stopped. The next RCT was Chintu
[in 2004]. In retrospect, I think that UNAIDS held up
the implementation of CPT in Africa. (MKI 2 27/02/
2009)
In contrast, in Zambia, after careful consideration the
government allowed three clinical trials to go ahead
[30].
The model of research conducted in each country was
therefore different. In Zambia, three experimental trials
were conducted (among HIV infected children, post par-
tum women and TB patients) and no specific opera-
tional research was undertaken [5,32]. In Malawi, three
pieces of operational research were conducted on the
effectiveness of CPT in HIV infected TB patients, with
the specific intent of informing policy and improving
the outcome of patients (MKI 12 18/03/2009). Similarly
in Uganda, two pieces of operational research were con-
ducted, examining efficacy, and addressing issues which
had been raised by the Ministry of Health: cost per
person, and the development of cotrimoxazole resistance
pathogens in diarrhoea and SP resistant malaria.
It was, therefore, the less epidemiologically robust
research conducted in Uganda and Malawi that appears
to have been more easily translated into practice. In
both countries the policy relevance of the operational
research was established as the study was being
designed, and both studies paid attention to the feasibil-
ity of implementation (a key concern raised in terms of
context, see above). According to one researcher:
In the beginning there was a list of questions that the
Ministry [of Health] raised: is [CPT] going to work or
not, will [CPT] increase resistance, is [CPT] going to be
too costly for us? So we embedded a cost effectiveness
plan from the very beginning and we made sure that we
spent the time answering those other questions. We
showed that it was effective, we showed that it was cost
effective, in fact it was cost saving, we looked to see
whether it increased resistance in malaria and saw that
it actually decreased the resistance to Fansidar. We trea-
ted those questions seriously, we answered them scientifi-
cally, effectively and they happened to be answered in
support of the provision of cotrimoxazole. (UKI9 21/01/
2010)
In Zambia, while the experimental trials clearly
showed the efficacy of CPT in an area of high bacterial
resistance, no data regarding the feasibility of implemen-
tation was provided at that time. One senior policy
maker argued:
In principle people agreed [with the research results]
but then you need to quantify and buy the cotrimoxa-
zole. These things were never worked out, you know the
CHAP study does not give those parameters so those
were the things that were not worked out and we needed
to have the funding available to procure the cotrimoxa-
zole if it was going to be universally applied. Those were
the challenges. (ZKI 15 28/10/09)
Further, the results of the paediatric CHAP (cotrimox-
azole as prophylaxis against opportunistic infections in
HIV-infected Zambian children) trial were interpreted
by senior clinicians and policy makers as being of
importance for clinical decision making, but not neces-
sarily requiring a new national policy (ZKI 8, 10/10/09,
ZKI 15 28/10/09). The Zambian research results were
central in the development of the national policy in
Malawi in 2005 and important in the development of
policy in Uganda in the same year. It took a further two
years, however, before the national Zambian policies
and guidelines were published.
Links
The links element of the framework focused on the
importance of key actors and their interactions to
explain how research evidence can be taken up into
Hutchinson et al. Health Research Policy and Systems 2011, 9(Suppl 1):S6
http://www.biomedcentral.com/1478-4505/9/S1/S6
Page 6 of 10policy. In particular, it was found important to under-
stand the roles of policy networks, policy entrepreneurs
(individuals crucial to the development of the policy
who bridge other influential groups) and policy cham-
pions (groups of experts and policy makers providing
support to the policy entrepreneur).
Unsurprisingly, in each of the three countries, two
important networks were identified: researchers, who
were seen to be experts in the field; and policy makers
– the key actors who would be making decisions on
CPT. A third network of NGOs and implementing
actors was also identified by some respondents.
It was found that each successful policy process
appeared to be reliant on a policy entrepreneur, particu-
larly when there were other elements which posed bar-
riers to formation of a CPT policy (doubt over the
evidence relevance, or concerns of the impact of CPT
on other treatments). These entrepreneurs were able to
link between the research and policy networks, and also
to rally support for CPT when policy making apparently
stalled. In Zambia in 2004, and in the Malawi HIV Pro-
gramme in 2002 there was no policy entrepreneur iden-
tified who had been working for such changes (in
Malawi the entrepreneur was in the TB Programme).
Strikingly, the policy entrepreneurs in all three coun-
tries had similar backgrounds. They were physicians
either currently or previously involved in medical
research whom, while the policy was being developed,
were in senior policy positions in well funded organiza-
tions/programmes. They were, however, placed in differ-
ent institutions: with one in government (Malawi), one
at an NGO (Zambia) and one in a donor agency
(Uganda). One researcher in Malawi considered that
this institutional position of the policy entrepreneur was
also significant, allowing the government to have owner-
ship of the cotrimoxazole research. He argued:
It was very different when someone from the World
Health Organisation or someone from an academic insti-
tution goes to the MOH and says “Here is a study here
are the results and would you like to implement it?” In
the case of cotrimoxazole there was someone from the
Ministry of Health in a high position, very well respected,
a good researcher, and a good programme person. He
said, “Here are the results, we have been involved with
several partners, you have heard of this throughout.”
And the Ministry says “Yes, sure this is part of what we
have been involved with.” (MKI 12 18/03/2009)
The visibility of the entrepreneurs was variable: in
Malawi the policy entrepreneur was identified by 11 out
of 15 informants (including t h ep o l i c ye n t r e p r e n e u r
himself). In Zambia, the policy entrepreneur was identi-
fied by 3 out of 15 (including the policy entrepreneur);
and in Uganda, the policy entrepreneur was identified
by 5 out of 15 informants (including the policy
entrepreneur). In Malawi and Uganda, the policy entre-
preneurs were both involved in local research conducted
while in Zambia, the policy entrepreneur utilized the
results of research already undertaken to support his
case for a national CPT policy.
The policy entrepreneurs did not work alone, how-
ever. In each country they were surrounded by a sup-
portive group of influential actors termed here ‘policy
champions’. These were researchers and/or policy
makers, who provided support and expertise, helped to
drive the policy forward and who recruited support
from other physicians, policy makers and researchers.
The entrepreneurs may have been the ones who identi-
fied strategic points to press for change, and who linked
key groups, but they relied on these additional indivi-
duals for legitimacy and support. The largest network of
policy champions was in Malawi in 2002, and this group
was drawn from both researchers and policy makers,
enabling them to very effectively bridge the research-to-
policy gap. In Uganda, the policy champions were
drawn from researchers and NGOs (CDC/Uganda,
TASO and the MRC), actively recruiting other research-
ers and government policy makers to support the policy.
In Zambia, policy champions eventually emerged from
NGOs primarily funded by the United States govern-
ment, representing only one of the three networks
involved in policy making.
Additional file 3 summarises the key framework ele-
ments analysed here, and illustrates how they compare
between our three country case studies as well as their
interdependence.
Discussion
The comparison of the country studies demonstrates
how central a favourable healthcare context is to the
adoption of research into policy. This is most visible in
the case of the Malawi HIV Programme in 2002 and the
Zambia HIV Programme in 2004/2005. In the former,
the heavy emphasis on disease prevention through beha-
viour change, education and safe blood supplies left
almost no room for a bio-medical approach, and a lack
of interest in CPT (in contrast to the Malawi TB Pro-
gramme which was searching for biomedical interven-
tions). In Zambia (two years later), almost the reverse
issue appeared, with a highly politicised bio-medical
approach to HIV being dominated by a campaign to
scale up ARVs, and the striking results of the research
into CPT for HIV infected children were eclipsed. These
policy processes show how an unfavourable policy con-
text may make it difficult for policy development even
when a sound evidence base upon which policy can be
constructed exists.
Our analysis further illustrates how the evidence base is
an important aspect of the policy development process,
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policy development process for CPT began either with
attempts to collect national data (Malawi) or with the
publication of the trials in Cote d’Ivoire and the subse-
quent WHO/UNAIDS provisional recommendations for
Africa (Uganda and Zambia). The strength of evidence
was crucial: none of the governments in the three coun-
tries considered the WHO/UNAIDS provisional recom-
mendations to be sufficiently evidence based to be
implemented. In Malawi and Uganda, the coupling of
this lack of evidence with the widespread perception of
the usefulness of cotrimoxazole (and related drugs) as a
treatment which might be threatened by its use as a pro-
phylactic, was considered to be a powerful barrier to
scale-up. Yet, this research also demonstrates clearly that
while poor evidence may stall a policy process, even
when powerful research evidence is available to policy
makers, it does not necessarily get translated into policy:
in our three countries, the only country to conduct ran-
domized clinical trials took the longest amount of time
to create national policy on CPT.
Finally, there appears to be a critical point when the
policy implications of a piece of research evidence is
contested (as was the case during the Malawian 2002
policy process), when a powerful policy entrepreneur,
supported by policy champions can play a particularly
important role in driving policy forward. A comparison
of the two Malawian policy processes (in 2002 and
2005) is useful to demonstrate this as the same policy
entrepreneur was involved in both processes but played
very different roles. In 2002, he was highly active, and
was supported by policy champions who defended the
international research model when it was called into
question and, with support from senior civil servants,
drove the policy through. In contrast, in 2005 when
there was more research evidence available which was
almost universally accepted (the 2005 policy states that
there was unanimous agreement) he played more of an
administrative role, making sure that meetings took
place, that the evidence was reviewed, and ultimately
that the policy was written. Overall, the role of a policy
entrepreneur was crucial in all cases, and, as an active
agent, able to respond to and address barriers to policy
development; providing additional evidence when ques-
tions were raised about the evidence base (particularly
in Uganda and Malawi), making links between
researcher and policy maker networks (most effectively
in Malawi but also in Uganda and Zambia), and linking
supportive policy champions with the evidence needed
and the correct policy audience (in all three countries).
Conclusion
The fact that national policy making on cotrimoxazole
prophylaxis was varied, in terms of the content and time
taken to reach a decision on its implementation in
Malawi, Uganda and Zambia, demonstrates that national
level variables must be considered to explain the uptake
of evidence into policy settings. In our analysis the local
context, interpretation of the evidence, and the nature
of the links between policy makers and researchers were
seen to both drive and stall the policy process. This
three country study further reinforces the importance of
understanding how these different facets of the policy
process are interdependent. It shows the importance of
af a v o u r a b l ep o l i c yc o n t e x ti nw h i c hap o l i c ye n t r e p r e -
neur can emerge; and the ways in which a well con-
nected policy entrepreneur can act to overcome other
obstacles, driving policy change when outstanding ques-
tions about the evidence may remain.
The development of the national CPT policy and
guidelines across these countries reinforces the impor-
tance of analysing research-policy linkages with specific
reference to country variables. As a retrospective analysis
such as this, it enables us to better explain and under-
stand the evidence to policy process. Yet this understand-
ing can be used by policy making actors concerned with
future use of evidence in policy as well, to help predict
potential obstacles, or opportunities, for getting evidence
into policy. Such prospective analyses are rare, but can be
conducted by researchers and research funders early in
the research cycle to ensure the right linkages with local
representatives are in place for better evidence uptake
once findings are available. The cross-country compari-
son has helped to validate and explore the usefulness of
one specific framework, designed for developing country
settings in particular. Improving the understanding of
these processes can help to explain existing cases of the
use (or non-use) of evidence in policy making, but can
potentially also inform future strategies to bridge the
research-policy gaps and improve the uptake of evidence
in decision making.
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